Our Focus — Step 4


Step 4 — Our current treks

Making genomic test results actionable

Elevation Oncology applies all of its insights towards the development of targeted therapies for novel driver alterations with high unmet patient needs.


Our first summit: NRG1 fusions

Our first clinical trial, CRESTONE (pronounced CRESS-tone), is a Phase 2 study of seribantumab in cancer patients with a solid tumor of any origin that expresses a genomic change called an NRG1 fusion. The CRESTONE study is actively enrolling patients now. 

Group 3 Driver Alteration Paired targeted Therapy Pre-INDPhase 1Phase 2RegistrationalNRG1 fusions Seribantumab (anti-HER3 mAb)